In regenerative medicine, additive manufacturing (AM) is a fabrication process that builds structures layer by layer, allowing precise control over material placement to produce complex, customized designs. While 3D printing is often used interchangeably, AM is a broader term that encompasses various techniques beyond extrusion-based printing.
In InterLynk, AM integrates multiple techniques - including extrusion, photocuring, and Melt Electro Writing (MEW) - to construct multimaterial scaffolds with properties tailored for tissue-specific regeneration. Instead of relying on a single fabrication method, different biomaterials are processed in ways that optimize their structural and biological integration.
InterLynk employs advanced virtual modeling tools to optimize scaffold design before fabrication, ensuring structures that closely mimic natural tissues. These tools allow for:
from medical imaging (MRI, CT scans).
to fine-tune material interactions during printing.
to predict scaffold performance under physiological conditions.
To enable the printing of InterLynk’s cutting-edge personalized bio-inks, existing AM systems are being upgraded with:
A specialized extrusion-based AM system with built-in light curing at the dispensing nozzle, allowing for immediate solidification of photosensitive materials. This Print and Cure technology, developed in collaboration with InterLynk partner EnvisionTEC, enhances precision and stability in bioprinting by combining printing and curing in a single step.
The system can combine extrusion-based AM with Melt Electro Writing (MEW) in a single part, enabling hierarchical structures with enhanced mechanical properties.
A computational framework optimizing printing speed, light intensity, and material interactions to improve structural integrity and biomaterial integration
MEW is an advanced electrospinning technique that produces ultrafine polymer fibers with micron-scale precision. In InterLynk, MEW is used to:
A major challenge in regenerative medicine is seamlessly connecting soft and hard tissue interfaces. InterLynk’s multimaterial AM strategy overcomes this by: